 DSUVIA 2q21 revenues were below my and market expectations. But management provided further details regarding the Europe out-licensing agreement for DSUVIA and the in-licensing agreements. And Formulary Approvals have picked up substantially also indicating gradually increasing interest in the product. Management mentioned discussions about a DSUVIA out-licensing to the Asia-Pacific region. 